Comparative Pharmacology
Head-to-head clinical analysis: SYNERCID versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNERCID versus XIFYRM.
SYNERCID vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synercid is a combination of two streptogramin antibiotics, quinupristin and dalfopristin, which bind to the 50S bacterial ribosome and inhibit protein synthesis. Quinupristin binds to the 23S rRNA near the peptidyl transferase center, while dalfopristin binds to a nearby site and enhances quinupristin's binding. The synergistic effect results in irreversible inhibition of bacterial protein synthesis.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
7.5 mg/kg IV every 8 hours, administered as a 60-minute infusion.
500 mg orally twice daily with food.
None Documented
None Documented
The terminal elimination half-life is approximately 0.85 hours for dalfopristin and 1.3 hours for quinupristin; however, the active metabolite of quinupristin has a half-life of about 3.5 hours, supporting twice-daily dosing.
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Primarily hepatic metabolism with biliary excretion; approximately 15% of the dalfopristin dose and 32% of the quinupristin dose are excreted unchanged in feces; renal excretion is minor (<5% for both components).
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category C
Category C
Antibiotic
Antibiotic